Advertisement

Topics

Catalent to Acquire Gene Therapy Leader Paragon Bioservices for $1.2 Billion

09:20 EDT 16 Apr 2019 | Speciality Pharma Journal

SOMERSET, N.J. and BALTIMORE, April 15, 2019 /PRNewswire/ — Catalent, Inc. (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, today announced they have entered into a definitive …

Original Article: Catalent to Acquire Gene Therapy Leader Paragon Bioservices for $1.2 Billion

NEXT ARTICLE

More From BioPortfolio on "Catalent to Acquire Gene Therapy Leader Paragon Bioservices for $1.2 Billion"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...